M&A Transactions
Life Sciences M&A Report: Half-Year 2024
The first half of 2024 has been an active year for M&A’s in the life sciences industry. The overall data reflects significant quarterly fluctuations in the total value and count of M&A deals within the life sciences sector from 2022 to mid-2024, highlighting shifting market priorities and potential external influences such as regulatory changes or […]
27 Nov 2024
Read moreLife Sciences M&A Report 2023
2023 showed slow signs of recovery for global life science M&A activity compared to the previous year, both in terms of the number and value of deals. While the macroeconomic challenges and uncertainty in the geopolitical landscape that fueled the 2022 slowdown carried over into 2023, there are indications that dealmakers were approaching 2023 with […]
22 May 2024
Read moreThe Current State of M&A Activity in the Life Sciences Industry
The life sciences industry is no stranger to mergers and acquisitions (M&As), helping to expand product portfolios, access new markets and pursue new innovations, amongst a myriad of other reasons. In this article, we will look at the current state of M&A activity based on data from the Biotechgate database, with insights on where the […]
20 Oct 2023
Read moreLife Sciences M&A Report: Half-Year 2023
In the first half of 2023, the slowdown in terms of global life sciences M&A deal-making experienced in the second half of 2022 has continued to show its effects. Anticipated as a year of recovery, 2023 was expected to leverage M&A as a means to adapt to rapidly changing market conditions. However, while it remains […]
20 Oct 2023
Read moreIntroducing M&A deals to Biotechgate
Biotechgate is continuously working on enhancements and new tools to boost the experience for our users. Currently, Biotechgate is developing a new release, which is planned for early 2024: Among the various new features that subscribers can look forward to, one in particular worth highlighting revolves around M&A deals and is unique on the market […]
20 Oct 2023
Read moreLife Sciences M&A Report 2022
In line with the broader negative trend in overall M&A investment worldwide, the global M&A activity in the life sciences industry experienced a slowdown in 2022: M&A activity declined significantly in both the number and value of deals compared to the previous year. However, there is hope that 2023 will be a more active year […]
27 Mar 2023
Read moreThe 8 Largest Biopharma M&A Deals of 2022 (Jan-Sep)
Despite 2022 being a relatively quiet year for M&A activity within the biopharma space, especially when compared to 2021, a number of prominent deals have taken place. Find out the 8 largest M&A deals of the year so far in order of the total amount. 8. Zogenix Acquired by: UCB Amount: USD 1.9bn After Zogenix’s […]
19 Oct 2022
Read more